Erratum: Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial (The Lancet (2017) 390(10114) (2779–2789) (S0140673617326417) (10.1016/S0140-6736(17)32641-7));Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet

Volumn 390, Issue 10114, 2017, Pages 2779-2789

  Colombel, Jean Frederic ^a   Panaccione, Remo ^b   Bossuyt, Peter ^c   Lukas, Milan ^d,e   Baert, Filip ^f   Vaňásek, Tomas ^g   Danalioglu, Ahmet ^h   Novacek, Gottfried ⁱ   Armuzzi, Alessandro ^j   Hébuterne, Xavier ^k,l   Travis, Simon ^m   Danese, Silvio ^n,o   Reinisch, Walter ⁱ   Sandborn, William J ^p   Rutgeerts, Paul ^q   Hommes, Daniel ^r   Schreiber, Stefan ^s   Neimark, Ezequiel ^t   Huang, Bidan ^t   Zhou, Qian ^t   Mendez, Paloma ^u   Petersson, Joel ^t   Wallace, Kori ^t   Robinson, Anne M ^t   Thakkar, Roopal B ^t   D'Haens, Geert ^v   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c IMELDA HOSPITAL   (Belgium)

^d Surgery   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f AZ Delta   (Belgium)

^g Hepato Gastroenterologie HK   (Czech Republic)

^h BEZMIALEM VAKIF UNIVERSITY   (Turkey)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^k Service de Gastro entérologie et Nutrition Clinique   (France)

^l UNIVERSITÉ CÔTE D'AZUR   (France)

^m OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁿ HUMANITAS UNIVERSITY   (Italy)

^o HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^p UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^q UNIVERSITY OF LEUVEN   (Belgium)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^t ABBVIE INC   (United States)

^u St Louis University (Madrid Campus)   (Spain)

^v ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; PREDNISONE; ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BODY WEIGHT; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; ILEOCOLONOSCOPY; IMMUNOMODULATION; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT MONITORING; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCREENING TEST; SMOKING; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; C-REACTIVE PROTEIN; CROHN DISEASE; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85033669878     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32909-4     Document Type: Erratum

References (31)

1. Peyrin-Biroulet, L, Loftus, EV Jr, Colombel, JF, Sandborn, WJ, The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 105 (2010), 289–297.
2. Thia, KT, Sandborn, WJ, Harmsen, WS, Zinsmeister, AR, Loftus, EV Jr, Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 139 (2010), 1147–1155.
3. Torres, J, Mehandru, S, Colombel, JF, Peyrin-Biroulet, L, Crohn's disease. Lancet 389 (2017), 1741–1755.
4. Khanna, R, Bressler, B, Levesque, BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386 (2015), 1825–1834.
5. Lichtenstein, GR, Feagan, BG, Cohen, RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006), 621–630.
6. Osterman, MT, Sandborn, WJ, Colombel, JF, et al. Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol 111 (2016), 1806–1815.
7. Colombel, JF, Mahadevan, U, Inflammatory bowel disease 2017: innovations and changing paradigms. Gastroenterology 152 (2017), 309–312.
8. Peyrin-Biroulet, L, Sandborn, W, Sands, BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
9. Best, WR, Becktel, JM, Singleton, JW, Kern, F Jr, Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
10. Mosli, MH, Zou, G, Garg, SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 802–820.
11. Colombel, JF, Sandborn, WJ, Reinisch, W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
12. Rutgeerts, P, Van Assche, G, Sandborn, WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142 (2012), 1102–1111 e2.
13. Feagan, BG, Lémann, M, Befrits, R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 18 (2012), 152–160.
14. Schreiber, S, Reinisch, W, Colombel, JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 7 (2013), 213–221.
15. Colombel, JF, Rutgeerts, PJ, Sandborn, WJ, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 414–422.
16. Colombel, JF, Sandborn, WJ, Rutgeerts, P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
17. D'Haens, G, Baert, F, van Assche, G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008), 660–667.
18. Tibble, JA, Sigthorsson, G, Bridger, S, Fagerhol, MK, Bjarnason, I, Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000), 15–22.
19. Heida, A, Park, KT, van Rheenen, PF, Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis 23 (2017), 894–902.
20. D'Haens, G, Ferrante, M, Vermeire, S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18 (2012), 2218–2224.
21. Solem, CA, Loftus, EV Jr, Tremaine, WJ, Harmsen, WS, Zinsmeister, AR, Sandborn, WJ, Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005), 707–712.
22. Liverani, E, Scaioli, E, Digby, RJ, Bellanova, M, Belluzzi, A, How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 22 (2016), 1017–1033.
23. Florin, TH, Paterson, EW, Fowler, EV, Radford-Smith, GL, Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 41 (2006), 306–311.
24. Jones, J, Loftus, EV Jr, Panaccione, R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 6 (2008), 1218–1224.
25. Colombel, JF, Jharap, B, Sandborn, WJ, et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther 45 (2017), 50–62.
26. Osterman, MT, Sandborn, WJ, Colombel, JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 146 (2014), 941–949.
27. Burmester, GR, Panaccione, R, Gordon, KB, McIlraith, MJ, Lacerda, AP, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 72 (2013), 517–524.
28. Colombel, JF, Sandborn, WJ, Rutgeerts, P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 104 (2009), 1170–1179.
29. Khanna, R, Zou, GY, D'Haens, G, et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 65 (2016), 1119–1125.
30. Mary, JY, Modigliani, R, Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989), 983–989.
31. Cote-Daigneault, J, Peerani, F, Katsanos, K, et al. Agreement between Crohn's disease endoscopy severity scores derived from live local, delayed local video-recorded and central readings. Gastroenterology 152:suppl 1 (2017), S209–S210.